EP 904 PILL - IDENTIFICATION, MECHANISM OF ACTION, SIDE EFFECTS

The pill imprinted with EP 904 is Lorazepam 0.5 mg, a prescription medication belonging to the benzodiazepine class of drugs (Schedule IV controlled substance).

Pill Identification

Attribute – Visual / Clinical Properties

Imprint – EP 904 on one side, plain on the reverse
Color & Shape – White, round, flat-faced with a beveled edge
Active Ingredient – Lorazepam 0.5 mg
Drug Class – Benzodiazepine (Central Nervous System Depressant)
DEA Schedule – Schedule IV Controlled Substance (CIV)

Mechanism of Action

Lorazepam enhances the action of gamma-aminobutyric acid (GABA), the primary inhibitory neurotransmitter in the central nervous system (CNS).

Receptor Binding: Lorazepam binds to a specific site on the receptor complex.
Enhanced Inhibition: This binding acts as a positive allosteric modulator, increasing the frequency of chloride channel openings when GABA binds.
Hyperpolarization: The influx of chloride ions hyperpolarizes the postsynaptic neuron, making it less likely to fire an action potential.
Clinical Effect: The resulting increase in CNS inhibition produces anxiolytic (anti-anxiety), sedative, anticonvulsant, muscle-relaxant, and amnestic effects.

Indications and Dosing Guidelines

Lorazepam is FDA-approved for the management of anxiety disorders or the short-term relief of anxiety symptoms (or anxiety associated with depressive symptoms). It is also commonly used off-label or in specialized protocols for status epilepticus, acute agitation, and chemotherapy-induced nausea.

Anxiety Management: The usual starting dose for adults is 1 to 3 mg/day divided into 2 to 3 doses. The overall daily range is typically 2 to 6 mg/day in divided doses (with the largest dose taken before bedtime).
Insomnia Due to Anxiety: A single daily dose of 1 to 2 mg taken at bedtime.
Elderly or Debilitated Patients: An initial dosage of 0.5 mg to 1 mg/day in divided doses, titrated as needed to reduce the risk of excessive sedation or ataxia.
Note: Dosage must always be individualized by a licensed healthcare provider to avoid excessive sedation or motor impairment.

Common and Serious Side Effects

Common Adverse Effects

Somnolence and Sedation: Extreme drowsiness or lethargy.
Dizziness and Unsteadiness: Impaired coordination, increased risk of falls.
Weakness: Feeling physically fatigued or sluggish.
Cognitive Effects: Confusion, forgetfulness, or anterograde amnesia (difficulty forming new memories).

Serious Adverse Effects

Respiratory Depression: Abnormally slow or shallow breathing, especially when combined with other CNS depressants.
Paradoxical Reactions: Anxiety, agitation, restlessness, excitation, or aggressiveness (more common in pediatric or elderly populations).
Severe Allergic Reactions: Anaphylaxis or angioedema (swelling of lips, tongue, or throat).

Black Box Warnings and Precautions

The U.S. Food and Drug Administration (FDA) issues a Boxed Warning for lorazepam regarding several critical safety risks:

Risk from Concomitant Use with Opioids: Taking lorazepam together with opioids (such as oxycodone, morphine, or fentanyl) can lead to profound sedation, severe respiratory depression, coma, and death. Concomitant prescribing should be limited to patients for whom alternative treatment options are inadequate.
Abuse, Misuse, and Addiction: Lorazepam exposes users to the risks of abuse and misuse, which can lead to overdose and death. Assess each patient’s risk prior to prescribing and monitor throughout treatment.
Physical Dependence and Withdrawal: Chronic use of lorazepam can cause physical dependence. Abrupt discontinuation or rapid dose reduction can trigger acute withdrawal symptoms, including seizures, hallucinations, tremors, psychosis, and life-threatening status epilepticus. Tapering off the medication under medical supervision is mandatory.